Thrombin inhibitors identified by computer-assisted multiparameter design.
暂无分享,去创建一个
Andreas Schwienhorst | Michael Gebinoga | Martin Wiesenfeldt | Christian Merkwirth | Daniel Riester | Marcel Thürk | Stefan Kamphausen | W. Bode | F. Wirsching | D. Riester | A. Schwienhorst | C. Merkwirth | Wolfram Bode | Martin Wiesenfeldt | Gabriela Salinas | G. Salinas | Jörg Stürzebecher | M. Gebinoga | R. Friedrich | Rainer Friedrich | Frank Wirsching | Martina Keller | Ruediger Goetz | Martina Keller | S. Kamphausen | J. Stürzebecher | Ruediger Goetz | M. Thürk
[1] Mary L. Westbrook,et al. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. , 1991 .
[2] Barry Robson,et al. PRO_LIGAND: An approach to de novo molecular design. 3. A genetic algorithm for structure refinement , 1995, J. Comput. Aided Mol. Des..
[3] Y. Tsuda,et al. Development of plasma kallikrein selective inhibitors. , 1992, Biopolymers.
[4] Andreas Schwienhorst,et al. Genetic algorithm for the design of molecules with desired properties , 2002, J. Comput. Aided Mol. Des..
[5] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[6] A Abrahamsson,et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.
[7] Sean T. Quinn,et al. Automated Assay Optimization with Integrated Statistics and Smart Robotics , 2000, Journal of biomolecular screening.
[8] J. Stürzebecher,et al. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. , 1999, Thrombosis research.
[9] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[10] J. Stürzebecher,et al. Influence of Structural Variations in Peptidomimetic 4-Amidinophenylalanine-Derived Thrombin Inhibitors on Plasma Clearance and Biliary Excretion in Rats , 2002, Pharmaceutical Research.
[11] T. Steinmetzer,et al. Structure-Activity Relationships of New NAPAP-Analogs , 2001, Journal of enzyme inhibition and medicinal chemistry.
[12] Petra Schneider,et al. De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks , 2000, J. Comput. Aided Mol. Des..
[13] T. Steinmetzer,et al. Advances in the development of thrombin inhibitors , 2001, Expert opinion on investigational drugs.
[14] W. Schumacher,et al. Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis. , 1994, European journal of pharmacology.
[15] G Klebe,et al. Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. , 2001, Journal of molecular biology.
[16] S. Gardell,et al. Assessment of Thrombin Inhibitor Efficacy in a Novel Rabbit Model of Simultaneous Arterial and Venous Thrombosis , 1998, Thrombosis and Haemostasis.
[17] W. Schumacher,et al. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. , 1996, Journal of cardiovascular pharmacology.
[18] S. Pehrsson,et al. Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes , 1998, Thrombosis and Haemostasis.